Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

January 13, 2022

Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19

January 4, 2022

Gritstone Announces Presentations during Three Upcoming Investor Conferences

December 30, 2021

Gritstone Announces Changes to Its Board of Directors

December 17, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 13, 2021

Gritstone bio Added to the Nasdaq Biotechnology Index

December 13, 2021

Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant

December 6, 2021

The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

November 29, 2021

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 23, 2021

Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

November 10, 2021

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

© 2023 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Contact

socials

Top